Akela Pharma Inc and Nventa Biopharmaceuticals Corporation have merged. The public company will retain Akela’s name, will operate under Akela’s management and will continue to be listed on the Toronto Stock Exchange under the ticker symbol AKL. Two directors of Nventa, Gregory McKee and Robert Rieder, have been appointed to the board of directors of Akela, effective at closing.
May 22, 2009...12:49 pm
Merger of Akela Pharma and Nventa Biopharmaceuticals
Jump to Comments
